A recent clinical trial employing Escherichia coli-produced rhIL-15, administered to patients with metastatic malignant melanoma or metastatic renal cell cancer, demonstrated safety of IL-15 treatment of patients with metastatic malignancy. Here, IL15 is linked to metastatic melanoma.